» Articles » PMID: 16703622

Prevalence of Glucose Intolerance in Primary Hyperparathyroidism and the Benefit of Parathyroidectomy

Overview
Specialty Endocrinology
Date 2006 May 17
PMID 16703622
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Increased prevalence of diabetes mellitus (DM) in primary hyperparathyroidism (PHPT) is established, but not glucose intolerance (GI), nor benefit from parathyroidectomy on GI. We determined these during management of a continuous series of patients with PHPT routinely followed after surgery.

Patients And Methods: WHO criteria classified 75 g oral glucose tolerance tests (OGTT) in 51/54 consecutively proven PHPT patients, into normal glucose tolerance (NGT), DM, impaired glucose tolerance (IGT) or impaired fasting glucose (IFG); GI was derived by adding those with DM and IGT/IFG. OGTT were repeated after parathyroidectomy (mean follow up 2.4 +/- SD 1.6 years). Paired student t tests were used to compare fasting and 2-h plasma glucose (PG).

Results: At presentation 32/54 patients (59%) had NGT, 10 IGT/IFG (19%) and 12 type 2 DM (22%), nine newly diagnosed. Before parathyroidectomy 17/35 patients had NGT (49%), 18 GI (51%), 12 DM (34%) and 6 IGT/IFG (17%). Five out of six patients with IGT/IFG had NGT, one with NGT developed IGT. At completion 23 patients (66%) had NGT, 12 GI (34%), 4 IGT/IFG (11%) and 8 DM (23%). After parathyroidectomy fasting and 2-h. PG fell in 30/34 normocalcaemic patients not on hypoglycaemic agents, 5.6 +/- 1.0 to 5.4 +/- 0.8 mmol/l, 7.2 +/- 3.0 to 6.3 +/- 3.1 mmol/l (p < 0.05, p < 0.01).

Conclusions: 1. At presentation with PHPT, OGTT commonly identifies Type 2 DM and GI.2. After successful parathyroidectomy fasting and 2-h. PG fall significantly (p < 0.05, p < 0.01). DM and IGT/IFG often ameliorates to IGT or NGT, persistently.

Citing Articles

Association Between Primary Hyperparathyroidism and Secondary Diabetes Mellitus: Findings From a Scoping Review.

Barnett M Cureus. 2023; 15(6):e40743.

PMID: 37350980 PMC: 10284313. DOI: 10.7759/cureus.40743.


Parathyroid diseases and metabolic syndrome.

Modica R, Liccardi A, Minotta R, Benevento E, Cannavale G, Colao A J Endocrinol Invest. 2023; 46(6):1065-1077.

PMID: 36773188 PMC: 10185585. DOI: 10.1007/s40618-023-02018-2.


Effect of Parathyroidectomy on Metabolic Homeostasis in Primary Hyperparathyroidism.

Frey S, Bourgade R, Le May C, Croyal M, Bigot-Corbel E, Renaud-Moreau N J Clin Med. 2022; 11(5).

PMID: 35268464 PMC: 8911089. DOI: 10.3390/jcm11051373.


Assessment of insulin resistance in patients with primary hyperparathyroidism before and after Parathyroidectomy.

Nikooei Noghani S, Milani N, Afkhamizadeh M, Kabiri M, Bonakdaran S, Vazifeh-Mostaan L Endocrinol Diabetes Metab. 2021; 4(4):e00294.

PMID: 34505755 PMC: 8502214. DOI: 10.1002/edm2.294.


The influence of parathyroidectomy on cardiometabolic risk factors in patients with primary hyperparathyroidism: a systematic review and meta-analysis.

Yavari M, Feizi A, Haghighatdoost F, Ghaffari A, Rezvanian H Endocrine. 2020; 72(1):72-85.

PMID: 33057988 DOI: 10.1007/s12020-020-02519-7.